XML 32 R26.htm IDEA: XBRL DOCUMENT
v3.26.1

NATURE OF OPERATIONS AND LIQUIDITY - Additional Information (Details) - USD ($) |  |  | 1 Months Ended | 3 Months Ended |
--- | --- | --- | --- | --- | ---
Oct. 23, 2025 | Jan. 19, 2021 | Jan. 31, 2021 | Mar. 31, 2026 | Mar. 31, 2025 | Dec. 31, 2025
Nature Of Operations And Liquidity [Line Items] |  |  |  |  |  |
Accumulated deficit |  |  |  | $ 814,204,124 |  | $ 688,799,740
Net cash used in operating activities |  |  |  | 5,427,064 | $ 4,071,960 |
Cash, cash equivalents, restricted cash and marketable securities |  |  |  | $ 78,200,000 |  |
Preferred stock, shares issued |  |  |  | 0 |  | 0
Series A Convertible Preferred Stock | Private Placement |  |  |  |  |  |
Nature Of Operations And Liquidity [Line Items] |  |  |  |  |  |
Proceeds from exchange of preferred stock | $ 80,000,000 |  |  |  |  |
Preferred stock, shares issued | 80,000 |  |  |  |  |
Tranche A Warrants | Private Placement |  |  |  |  |  |
Nature Of Operations And Liquidity [Line Items] |  |  |  |  |  |
Warrants exercised | 80,000 |  |  |  |  |
Tranche B Warrants | Private Placement |  |  |  |  |  |
Nature Of Operations And Liquidity [Line Items] |  |  |  |  |  |
Potential proceeds from excersie of warrants | $ 40,000,000 |  |  |  |  |
Warrants exercised | 40,000 |  |  |  |  |
Maximum | Private Placement |  |  |  |  |  |
Nature Of Operations And Liquidity [Line Items] |  |  |  |  |  |
Gross proceeds before deducting placement agent fees and other expenses | $ 200,000,000 |  |  |  |  |
Seltorexant |  |  |  |  |  |
Nature Of Operations And Liquidity [Line Items] |  |  |  |  |  |
Additional milestone payments |  |  | $ 80,000,000 |  |  |
Potential Future Milestone Payments |  |  | 80,000,000 |  |  |
Seltorexant | Royalty Pharma |  |  |  |  |  |
Nature Of Operations And Liquidity [Line Items] |  |  |  |  |  |
Up front payment |  | $ 60,000,000 | 60,000,000 |  |  |
Additional milestone payments |  |  | 95,000,000 |  |  |
Potential Future Milestone Payments |  |  | $ 95,000,000 |  |  |

X
- Definition Cash, cash equivalents, restricted cash and marketable securities. + References No definition available. + Details
Name: | nerv_CashCashEquivalentsRestrictedCashAndMarketableSecurities
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Gross proceeds, before deducting placement agent fees and other expenses. + References No definition available. + Details
Name: | nerv_GrossProceedsBeforeDeductingPlacementAgentFeesAndOtherExpenses
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum potential proceeds from exercise of warrants. + References No definition available. + Details
Name: | nerv_MaximumPotentialProceedsFromExerciseOfWarrants
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Nature of operations and liquidity. + References No definition available. + Details
Name: | nerv_NatureOfOperationsAndLiquidityLineItems
Namespace Prefix: | nerv_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential future milestone payments. + References No definition available. + Details
Name: | nerv_PotentialFutureMilestonePayments
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | nerv_UpfrontPayment
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of warrants or rights outstanding. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_NetCashProvidedByUsedInOperatingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of accumulated undistributed earnings (deficit). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=nerv_SeriesAConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=nerv_TrancheAWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=nerv_TrancheBWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=nerv_SeltorexantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nerv_RoyaltyPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |